Form 4: NEUROONE CTO Sells Shares for Tax Obligations

NEUROONE MEDICAL TECHNOLOGIES Corp's Chief Technology Officer, Steve Mertens, disposed of 906 common shares to cover tax liabilities.

Summary

• Steve Mertens, Chief Technology Officer of NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC), reported a change in beneficial ownership.
• On December 31, 2025, Mertens disposed of 906 shares of Common Stock.
• The transaction was coded 'F', indicating shares withheld to cover tax liabilities.
• The shares were disposed of at a price of $0.758 per share.
• Following this transaction, Mertens directly beneficially owns 160,423 shares of Common Stock.
• The transaction was made pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 5

Explanation: The transaction is a routine disposition of shares for tax withholding purposes (Code F), which is a non-discretionary event and generally does not indicate a change in management's confidence or company fundamentals.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but the transaction type (tax withholding) suggests it is not indicative of a change in management's view of the company's prospects.

Key Dates

Recommendation

The filing details a routine, non-discretionary sale of a small number of shares by an officer to cover tax obligations. This type of transaction (Form 4, transaction code 'F') is common and typically does not signal any change in the company's fundamental outlook or management's confidence. Therefore, it provides no new information to warrant a change in investment recommendation.

Keywords

NEUROONE MEDICAL TECHNOLOGIES, NMTC, Steve Mertens, Form 4, Insider Transaction, Chief Technology Officer, Stock Disposition, Tax Withholding